InvestorsHub Logo
Followers 14
Posts 2462
Boards Moderated 0
Alias Born 12/17/2004

Re: misanthrope post# 15018

Tuesday, 11/27/2012 11:21:13 AM

Tuesday, November 27, 2012 11:21:13 AM

Post# of 22684
I believe there are 39 million shares trapped at $3.20 and under. I think we are just waiting for an event to start the Moass. But, I also believe the short have a plan to try to escape. For instance, concerning the EU approval not many know that all new drugs approved in the UK come with an automatic REMs. I think the shorts will try to use that for their advantage to spread FUD. I don't believe they are prepared for the eventual losses they will incurr and are currently shorting the highs down to gain some of the eventual losses back now. They have no choice really! The problem they are having is that they just don't have the shares available to short because of Reg Sho and the number of complaints registered at the SEC they are having a harder time manufacturing naked shares while being scrutinized so much. Today is the first day we have been off the Reg Sho list for the past 7 trading days. So, it would seem that brokers are forced to purchase shares to lend out for short purposes. This would validate the recent little rise and also the slight decrease so far today. Last I checked there were 450,000 shares available to short today while there were 330,000 shares available yesterday. Those 330,000 shares I don't understand because we were on the Reg SHO list for 7 consecutive days which means there were failures to deliver, so how were there 330,000 available to short?
It would seem to me that ARNA will have to prove themselves with good enrollment figures to finally get these sophisticated shorts off their back. Lot of powerful people involved, but no matter, revenue trumps all. I keep thinking how wrong the shorts were in their determination of Belviq approval. Also, Eisai is willing to pay out 200 million to us based on 250 Million in sales. 65 million as soon as DEA classification. Eisai paying 90% of post approval trial expenses for heart valve studies and 50% expenses for pediactric studies. This is a company that knows the science envolved, knows the market and thinks that Belviq will be its most successful drug ever after all those expenses. If you follow the money they also make a strong case and I trust their research over a H.F. and manipulaters anyday. So yes there will be an eventual MOASS. AJMO.